TRCT
CATX icon

Tower Research Capital (TRC)’s Perspective Therapeutics CATX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9K Sell
8,195
-3,480
-30% -$13.1K ﹤0.01% 3256
2026
Q1 		$48.7K Buy
11,675
+1,484
+15% +$6.27K ﹤0.01% 2757
2025
Q4 		$28K Buy
10,191
+3,317
+48% +$9.46K ﹤0.01% 2851
2025
Q3 		$23.6K Sell
6,874
-2,520
-27% -$9.19K ﹤0.01% 3155
2025
Q2 		$32.3K Sell
9,394
-266
-3% -$702 ﹤0.01% 3345
2025
Q1 		$20.6K Buy
9,660
+3,951
+69% +$11.9K ﹤0.01% 2934
2024
Q4 		$18.2K Buy
5,709
+3,509
+160% +$28.6K ﹤0.01% 3265
2024
Q3 		$29.4K Buy
+2,200
New +$29.3K ﹤0.01% 3014
2024
Q2 		– Sell
-1,088
Closed -$12.9K – 5710
2024
Q1 		$12.9K Sell
1,088
-839
-44% -$7.15K ﹤0.01% 3431
2023
Q4 		$7.75K Buy
1,927
+522
+37% +$1.47K ﹤0.01% 4584
2023
Q3 		$3.85K Buy
1,405
+283
+25% +$1.32K ﹤0.01% 4946
2023
Q2 		$7.5K Buy
1,122
+452
+67% +$2.74K ﹤0.01% 4563
2023
Q1 		$4K Sell
670
-1,481
-69% -$6.05K ﹤0.01% 5055
2022
Q4 		$5K Buy
+2,151
New +$7.09K ﹤0.01% 4841
2022
Q2 		– Sell
-1,380
Closed -$5K – 6095
2022
Q1 		$5K Buy
1,380
+572
+71% +$2.09K ﹤0.01% 5025
2021
Q4 		$3K Buy
+808
New +$4.31K ﹤0.01% 5424
2021
Q3 		– Sell
-96
Closed -$1K – 5789
2021
Q2 		$1K Sell
96
-347
-78% -$3.04K ﹤0.01% 5180
2021
Q1 		$5K Sell
443
-3,560
-89% -$53.8K ﹤0.01% 4653
2020
Q4 		$18K Buy
+4,003
New +$17.7K ﹤0.01% 3927
2016
Q1 		– Sell
-482
Closed -$5K – 4164
2015
Q4 		$5K Sell
482
-754
-61% -$9.39K ﹤0.01% 2939
2015
Q3 		$17K Buy
1,236
+262
+27% +$3.78K ﹤0.01% 1867
2015
Q2 		$14K Buy
974
+236
+32% +$3.82K ﹤0.01% 2399
2015
Q1 		$12K Buy
738
+408
+124% +$6.06K ﹤0.01% 2622
2014
Q4 		$5K Buy
+330
New +$5.23K ﹤0.01% 2684
2014
Q2 		– Sell
-40
Closed -$1K – 4054
2014
Q1 		$1K Buy
+40
New +$407 ﹤0.01% 4114

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Tower Research Capital (TRC)'s CATX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Perspective Therapeutics (CATX) stake by 30% in Q2 2026, selling an estimated $13.1K and leaving 8,195 shares worth $27.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3256.

Tower Research Capital (TRC) first reported a position in CATX in Q1 2014 and has held it in 25 quarters since. The position peaked at $48.7K in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Tower Research Capital (TRC) held 8,195 shares of Perspective Therapeutics worth $27.9K as of Q2 2026.
  • Tower Research Capital (TRC) sold 3,480 Perspective Therapeutics shares in Q2 2026, an estimated $13.1K.
  • Perspective Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3256 holding.
  • Tower Research Capital (TRC) first reported a position in Perspective Therapeutics in Q1 2014 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Perspective Therapeutics position peaked at $48.7K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.